Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction (MI-Holter)
Evaluation of the Prognostic Value of Long-term(2 Weeks) Electrocardiogram Analysis After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
This single-center, single-group study will evaluate the prognostic value of long-term electrocardiographic monitoring in adults with acute myocardial infarction who undergo primary percutaneous coronary intervention. After written informed consent, eligible participants will have a MEMO Patch2 long-term Holter monitor applied on the day of, or the day after, the procedure and will wear it for 2 weeks. The study will classify high-risk arrhythmias detected during monitoring and compare long-term clinical outcomes according to arrhythmia classification.
研究概览
详细说明
Patients presenting with acute myocardial infarction and undergoing primary percutaneous coronary intervention will be screened at Chungnam National University Hospital. Eligible adults who understand the study and provide written informed consent will be enrolled.
A MEMO Patch2 long-term Holter monitor will be attached on the day of, or the day after, the procedure. Participants will wear the device for 2 weeks and have it removed at an outpatient visit, after which the electrocardiographic recordings will be analyzed. Recorded arrhythmias include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes.
The primary objective is to classify high-risk arrhythmias detected by 2-week monitoring. The secondary objective is to compare long-term prognosis according to arrhythmia classification, including all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. Baseline diseases, laboratory results, social history, coronary intervention findings, prescribed medications, height, weight, and body mass index will also be collected. Statistical analyses described in the Protocol include descriptive statistics, t-tests, chi-square tests, Pearson correlation, multiple regression, multiple Cox regression, and Kaplan-Meier survival analysis, with a two-sided significance level of p<0.05.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:JunHyung Kim
- 电话号码:+82-042-280-8237
- 邮箱:william@cnu.ac.kr
学习地点
-
-
-
Daejeon、韩国、35015
- 招聘中
- Chungnam National University Hospital
-
接触:
- JunHyung Kim
- 电话号码:+82-042-280-8237
- 邮箱:william@cnu.ac.kr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adult aged 20 years or older.
- Diagnosed with STEMI and underwent primary percutaneous coronary intervention; or diagnosed with NSTEMI, underwent primary percutaneous coronary intervention, and meets at least one of the following conditions: (a) left ventricular ejection fraction ≤45% on echocardiography; (b) ventricular tachycardia, ventricular fibrillation, atrial fibrillation, or high-degree atrioventricular block during or after percutaneous coronary intervention (ventricular tachycardia is defined as ≥3 consecutive ventricular premature complexes); or (c) post-procedural TIMI flow grade 0-2 during percutaneous coronary intervention.
- Has received and understood an explanation of the study and signed the informed consent form.
Exclusion Criteria:
- Refuses to participate in the study.
- Is transferred to another hospital immediately after the procedure and cannot be followed.
- Is unable to express an intention to participate in the study, such as due to unconsciousness.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MEMO Patch2 Long-Term Holter Monitoring
Participants with acute myocardial infarction who undergo primary percutaneous coronary intervention will have a MEMO Patch2 long-term Holter monitor attached on the day of, or the day after, the procedure. The device will be worn continuously for 2 weeks and removed at an outpatient visit. Recorded arrhythmias will be analyzed, and long-term prognosis will be compared according to arrhythmia classification. |
MEMO Patch2 is a detachable long-term Holter monitoring device. It will be applied on the day of, or the day after, primary percutaneous coronary intervention and worn for 2 weeks to record arrhythmias that may be missed by in-hospital monitoring. It will be removed at an outpatient visit, and the recordings will then be analyzed.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Classification of High-Risk Arrhythmias
大体时间:At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
High-risk arrhythmias detected by MEMO Patch2 will be classified. Arrhythmias assessed include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes. |
At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Long-Term Prognosis According to Arrhythmia Classification
大体时间:Through study completion (anticipated 2026-12-31)
|
Long-term prognosis will be compared according to arrhythmia classification. Outcomes include all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. |
Through study completion (anticipated 2026-12-31)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- MI-Holter
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data collected in this study are not planned to be shared with external researchers. Any future sharing would require separate sponsor approval and compliance with applicable privacy, ethical, and institutional requirements.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.